PRCT (PROCEPT BioRobotics) Research & Development: $76.3 Mil (TTM As of Mar. 2026)


PRCT PROCEPT BioRobotics Corp PRCT
70 GF Score
Price $20.85
GF Value $91.98
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics Research & Development?

PROCEPT BioRobotics PRCT +1.16% 70 Research & Development is $76.3 Mil as of Mar. 2026. GuruFocus rates PRCT with a GF Score™ of 70/100 and a GF Value™ of $91.98 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PROCEPT BioRobotics's Research & Development for the three months ended in Mar. 2026 was $21.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $76.3 Mil.

PROCEPT BioRobotics  (NAS:PRCT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PROCEPT BioRobotics Research & Development Related Terms

PROCEPT BioRobotics Research & Development Historical Data

* Premium members only.

The historical data trend for PROCEPT BioRobotics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROCEPT BioRobotics Research & Development Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 18.99 28.98 48.45 62.30 71.28

PROCEPT BioRobotics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.40 17.63 18.19 19.06 21.47
PRCT
70GF Score
PROCEPT BioRobotics Corp PRCT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROCEPT BioRobotics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $76.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $76.3 Mil mean?
PROCEPT BioRobotics (PRCT) has a Research & Development of $76.3 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on PROCEPT BioRobotics and its competitors.
Is PROCEPT BioRobotics' Research & Development too high?
PROCEPT BioRobotics' current Research & Development is $76.3 Mil. Overall, PROCEPT BioRobotics has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' Research & Development compare to ALMR and AHCO?
PROCEPT BioRobotics' Research & Development of $76.3 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PROCEPT BioRobotics and its competitors. PROCEPT BioRobotics's current Research & Development is $76.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is $91.98, compared to a current price of $20.85 — trading 77.3% below its estimated fair value. The current Research & Development is $76.3 Mil. PROCEPT BioRobotics' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PROCEPT BioRobotics (PRCT), the current Research & Development is $76.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of $20.85 is trading 77.3% below its estimated GF Value™ of $91.98. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for PRCT:

  • Research & Development: $76.3 Mil
  • GF Value™: $91.98 vs. price of $20.85 (77.3% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:Mexico
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
70GF Score

Get the complete analysis for PRCT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.85
Price
$91.98
GF Value